Atlas Trials

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Clinical trial NCT07137416 · RECRUITING

Trial details

NCT number
NCT07137416
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast CarcinomaMetastatic HER2-Low Breast CarcinomaMetastatic HER2-Positive Breast CarcinomaMetastatic Hormone Receptor-Positive Breast CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Triple-Negative Breast CarcinomaUnresectable Breast CarcinomaUnresectable HER2-Low Breast Carcinoma
Start date
2026-10-05
Primary completion
2028-01-10
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.